Phase 1/2 × Ovarian Neoplasms × 1 year × Clear all
NCT04585750 2026-03-12

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

PMV Pharmaceuticals, Inc

Phase 1/2 Recruiting
300 enrolled
NCT07410494 2026-02-18

SELECT-CAR-NK

Essen Biotech

Phase 1/2 Recruiting
85 enrolled
NCT07410676 2026-02-18

EBNK-ST-001

Essen Biotech

Phase 1/2 Recruiting
83 enrolled
NCT07341737 2026-01-15

SL-28 for Advanced Solid Tumours

Second Life Therapeutics

Phase 1/2 Not yet recruiting
60 enrolled
NCT04260802 2026-01-12

A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers

Ocellaris Pharma, Inc.

Phase 1/2 Terminated
73 enrolled
NCT06943521 2025-12-11

A Study of MT-4561 in Patients With Various Advanced Solid Tumors

Tanabe Pharma America, Inc.

Phase 1/2 Recruiting
27 enrolled